viernes, 24 de octubre de 2025

FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belantamab-mafodotin-blmf-relapsed-or-refractory-multiple-myeloma

No hay comentarios:

Publicar un comentario